TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of Esomeprazole Once Daily for the Treatment of Gastroesophageal Reflux Disease (GERD) in Neonatal Patients, Including Premature and up to 1 Month Corrected Age
Brief Summary: The purpose of this study is to assess the difference between esomeprazole and placebo in the treatment of signs and symptoms as observed by 8-hour video and cardiorespiratory monitoring in neonatal patients.


Options:
A: Arm Label: Open Label Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Open Label Run In Esomeprazole | Arm Label: Double Blind Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Double Blind Esomeprazole | Arm Label: Double Blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double Blind Placebo | Intervention Type: DRUG; Name: Open Label Run In Esomeprazole; Assigned to Arm(s): Open Label Esomeprazole | Intervention Type: DRUG; Name: Double Blind Esomeprazole; Assigned to Arm(s): Double Blind Esomeprazole | Intervention Type: DRUG; Name: Double Blind Placebo; Assigned to Arm(s): Double Blind Placebo
B: Arm Label: Lansoprazole QD; Type: EXPERIMENTAL; Interventions: Drug: Lansoprazole microgranules suspension | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lansoprazole microgranules suspension; Assigned to Arm(s): Lansoprazole QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD
C: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
D: Arm Label: Rabeprazole 0.5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: rabeprazole | Arm Label: Rabeprazole 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: rabeprazole | Intervention Type: DRUG; Name: rabeprazole; Assigned to Arm(s): Rabeprazole 0.5 mg/kg | Intervention Type: DRUG; Name: rabeprazole; Assigned to Arm(s): Rabeprazole 1.0 mg/kg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG
Brief Summary: This is a phase I study to examine the safety and immunogenicity of MVA85A delivered intradermally into the deltoid region in volunteers who have recieved BCG in the past 20 years.


Options:
A: Intervention Type: BIOLOGICAL; Name: MVA85A (Tuberculosis vaccine); Assigned to Arm(s): N/A
B: Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: MVA 85A; Assigned to Arm(s): N/A
D: Intervention Type: BIOLOGICAL; Name: BCG (SSI Strain); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label Study of Continuous Therapy With Cyclosporine and Sirolimus Versus Induction With Cyclosporine and Sirolimus Followed by Continuous Therapy With Sirolimus in Renal Allograft Recipients
Brief Summary: To assess equivalence in the rates of functional graft survival at 12 months after transplantation in patients receiving continuous therapy with cyclosporine (CsA, Sandimmune, Neoral) and sirolimus versus induction with CsA and sirolimus followed by CsA elimination and concentration-controlled sirolimus.


Options:
A: Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclosporine; Assigned to Arm(s): N/A
B: Arm Label: Everolimus + Mycophenolate sodium; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Enteric-coated mycophenolate sodium, Drug: Corticosteroids | Arm Label: Cyclosporine + Mycophenolate sodium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclosporine, Drug: Enteric-coated mycophenolate sodium, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + Mycophenolate sodium | Intervention Type: DRUG; Name: Cyclosporine; Assigned to Arm(s): Cyclosporine + Mycophenolate sodium | Intervention Type: DRUG; Name: Enteric-coated mycophenolate sodium; Assigned to Arm(s): Cyclosporine + Mycophenolate sodium, Everolimus + Mycophenolate sodium | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): Cyclosporine + Mycophenolate sodium, Everolimus + Mycophenolate sodium
C: Arm Label: Low-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: High-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolic Acid (MPA), Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Mycophenolic Acid (MPA); Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Cyclosporine A (CsA); Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AUC monitored withdrawal of MMF or CNI | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: AUC monitored withdrawal of MMF or CNI | Intervention Type: DRUG; Name: AUC monitored withdrawal of MMF or CNI; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multidisciplinary Approach to Reduce Injury and Alcohol
Brief Summary: The purpose of this study is to determine whether a booster session is needed after a brief intervention upon initial admission to the emergency room (ER) in order to reduce the rate of alcohol-related injury recidivism.


Options:
A: Arm Label: 1 Brief Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief alcohol intervention | Arm Label: 2) Booster; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief alcohol intervention plus booster | Intervention Type: BEHAVIORAL; Name: Brief alcohol intervention; Assigned to Arm(s): 1 Brief Intervention | Intervention Type: BEHAVIORAL; Name: Brief alcohol intervention plus booster; Assigned to Arm(s): 2) Booster
B: Arm Label: 1 - enhanced MI; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Motivational Interview | Arm Label: 2- standard MI; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Motivational Interview or viewing DVD | Intervention Type: BEHAVIORAL; Name: Enhanced Motivational Interview; Assigned to Arm(s): 1 - enhanced MI | Intervention Type: BEHAVIORAL; Name: Standard Motivational Interview or viewing DVD; Assigned to Arm(s): 2- standard MI
C: Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: usual care | Arm Label: CHAT brief MI intervention; Type: EXPERIMENTAL; Interventions: Behavioral: CHAT brief MI intervention | Intervention Type: BEHAVIORAL; Name: CHAT brief MI intervention; Assigned to Arm(s): CHAT brief MI intervention | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): Usual Care
D: Arm Label: Motivational Interviewing (MI); Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing (MI) | Arm Label: Brief Adolescent Mindfulness (BAM); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Adolescent Mindfulness (BAM) | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing (MI); Assigned to Arm(s): Motivational Interviewing (MI) | Intervention Type: BEHAVIORAL; Name: Brief Adolescent Mindfulness (BAM); Assigned to Arm(s): Brief Adolescent Mindfulness (BAM)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multidisciplinary Approach to Reduce Injury and Alcohol
Brief Summary: The purpose of this study is to determine whether a booster session is needed after a brief intervention upon initial admission to the emergency room (ER) in order to reduce the rate of alcohol-related injury recidivism.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Personalised normative feedback (PNF) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Self-help material | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Personalised normative feedback (PNF); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Self-help material; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): 3
B: Arm Label: 1 Brief Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief alcohol intervention | Arm Label: 2) Booster; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief alcohol intervention plus booster | Intervention Type: BEHAVIORAL; Name: Brief alcohol intervention; Assigned to Arm(s): 1 Brief Intervention | Intervention Type: BEHAVIORAL; Name: Brief alcohol intervention plus booster; Assigned to Arm(s): 2) Booster
C: Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention | Intervention Type: BEHAVIORAL; Name: Brief intervention; Assigned to Arm(s): Counseling | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention based on motivational interviewing | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care including referral for treatment | Intervention Type: BEHAVIORAL; Name: Brief intervention based on motivational interviewing; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Standard Care including referral for treatment; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives
Brief Summary: Cardiovascular risk factors cluster in hyperandrogenic women - including those presenting with the polycystic ovary syndrome - in association with insulin resistance, obesity, and other metabolic disorders.

The present clinical trial intends to compare the effects of oral contraceptives and metformin on PCOS patients, focusing on classic and non-classic cardiovascular risk markers and indexes of cardiovascular performance, in order to whether or not, as suspected by previous data obtained in non-hyperandrogenic women, oral contraceptives worsen the cardiovascular risk profile of PCOS women, favoring the use of metformin if the latter actually ameliorates such a risk.


Options:
A: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Lifestyle Intervention | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Lifestyle Intervention | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Metformin, Placebo
B: Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ethynyl-estradiol plus cyproterone acetate; Assigned to Arm(s): N/A
C: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral metformin | Arm Label: Oral contraceptive; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral contraceptive | Intervention Type: DRUG; Name: oral metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: oral contraceptive; Assigned to Arm(s): Oral contraceptive
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction in Cirrhotic Patients With Ascites
Brief Summary: The purpose of this study is to determine whether the infusion of albumin 4 gr per liter of ascites removed is as effective as the infusion of albumin 8 gr per liter of ascites removed in the prevention of post-paracentesis circulatory dysfunction


Options:
A: Intervention Type: DRUG; Name: albumin 4 gr/L ascites removed; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: albumin 8 gr/L ascites removed; Assigned to Arm(s): N/A
B: Arm Label: Usual treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Human Albumin; Type: EXPERIMENTAL; Interventions: Drug: Human Albumin | Intervention Type: DRUG; Name: Human Albumin; Assigned to Arm(s): Human Albumin
C: Arm Label: Standard medical treatment plus albumin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diuretics plus human albumin | Arm Label: Standard medical treatment; Type: OTHER; Interventions: Drug: Diuretics (standard medical treatment) | Intervention Type: DRUG; Name: Diuretics plus human albumin; Assigned to Arm(s): Standard medical treatment plus albumin | Intervention Type: DRUG; Name: Diuretics (standard medical treatment); Assigned to Arm(s): Standard medical treatment
D: Arm Label: HES 130/0.4; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxyethyl starch 130/0.4 | Arm Label: Ringer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringers acetate | Intervention Type: DRUG; Name: 6% Hydroxyethyl starch 130/0.4; Assigned to Arm(s): HES 130/0.4 | Intervention Type: DRUG; Name: Ringers acetate; Assigned to Arm(s): Ringer acetate

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Two Arm, Open Label, Twelve Week Phase IIIb Study to Evaluate the Tolerability of Rebif (New Formulation) (IFN Beta-1a) and Betaseron (IFN Beta-1b) in IFN-naive Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Followed by a Single Arm, Eighty-two Week Minimum, Rebif (New Formulation) Only Safety Extension
Brief Summary: To evaluate the tolerability of a new formulation of rebif and Betaseron in subjects with relapsing-remitting multiple sclerosis (RRMS) by comparing the mean change in injection site pain scores from pre-injection to 30 minutes post therapy administration.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: New Formulation of rebif - human interferon beta-1a | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta -1b | Intervention Type: DRUG; Name: New Formulation of rebif - human interferon beta-1a; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Interferon beta -1b; Assigned to Arm(s): 2
B: Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012, Drug: Placebo | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD); Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BG00012 240 mg Twice Daily (BID), Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate; Assigned to Arm(s): Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)
C: Arm Label: GA 20 mg/mL every day; Type: ACTIVE_COMPARATOR; Interventions: Drug: GA 20 mg/mL | Arm Label: GA 40 mg/mL 3 times a week; Type: EXPERIMENTAL; Interventions: Drug: GA 40 mg/mL | Intervention Type: DRUG; Name: GA 20 mg/mL; Assigned to Arm(s): GA 20 mg/mL every day | Intervention Type: DRUG; Name: GA 40 mg/mL; Assigned to Arm(s): GA 40 mg/mL 3 times a week
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium I.V. (Esomeprazole Sodium) 40mg BID for up to 72 Hours
Brief Summary: This study is being done to see if Nexium I.V. can reduce and control stomach acid in mechanically ventilated, critically ill patients in an Intensive Care Unit setting.


Options:
A: Arm Label: Proton pump inhibitor (PPI); Type: EXPERIMENTAL; Interventions: Drug: Pantoprazole | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline (0.9%) | Intervention Type: DRUG; Name: Pantoprazole; Assigned to Arm(s): Proton pump inhibitor (PPI) | Intervention Type: OTHER; Name: Saline (0.9%); Assigned to Arm(s): Normal saline
B: Intervention Type: DRUG; Name: Esomeprazole Sodium; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole 20 mg daily | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: famotidine 40 mg daily | Intervention Type: DRUG; Name: esomeprazole 20 mg daily; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: famotidine 40 mg daily; Assigned to Arm(s): 2
D: Intervention Type: OTHER; Name: Biventricular pacing post cardiac surgery; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablets Regimens in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease
Brief Summary: This study's purpose is to evaluate the long-term safety and efficacy of tolvaptan versus placebo in patients with ADPKD.


Options:
A: Arm Label: ACE-I + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Placebo | Arm Label: ACE-I + ARB; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Telmisartan | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): ACE-I + ARB, ACE-I + placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): ACE-I + ARB | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): ACE-I + placebo
B: Arm Label: Tolvaptan; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): Tolvaptan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sirolimus | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Standard; Assigned to Arm(s): 1
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Candesartan | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Candesartan and Cilnidipine | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Candesartan plus non-CCB agents | Intervention Type: DRUG; Name: Candesartan; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Candesartan and Cilnidipine; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Candesartan plus non-CCB agents; Assigned to Arm(s): C

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Eight-Week, Randomized, Double-Blind Comparison of Guanfacine, Focalin XR, and the Combination, With a Twelve Month Open-Label Extension for the Treatment of ADHD in Pediatric Subjects Aged 7 to 14 Years
Brief Summary: This study will evaluate the effectiveness of a single drug versus a combination of drugs in treating attention deficit hyperactivity disorder in children.


Options:
A: Arm Label: A; Type: N/A; Interventions: Drug: Atomoxetine | Arm Label: B; Type: N/A; Interventions: Drug: stimulants (any approved ADHD medication) | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: stimulants (any approved ADHD medication); Assigned to Arm(s): B
B: Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): N/A
C: Arm Label: Group 1: Guan-Guan+Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guanfacine | Arm Label: Group 2: Placebo-Placebo+DMPH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate (MPH) | Arm Label: Group 3: Guan-Guan+DMPH (Comb); Type: EXPERIMENTAL; Interventions: Drug: Guanfacine, Drug: Methylphenidate (MPH) | Intervention Type: DRUG; Name: Guanfacine; Assigned to Arm(s): Group 1: Guan-Guan+Placebo, Group 3: Guan-Guan+DMPH (Comb) | Intervention Type: DRUG; Name: Methylphenidate (MPH); Assigned to Arm(s): Group 2: Placebo-Placebo+DMPH, Group 3: Guan-Guan+DMPH (Comb)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): 1

Answer: C